<![CDATA[Consensus Recommendations Address Key Controversies in Lymphoma Management]]>

Key Recommendations from Bridging the Gaps 2025MCL: Experts recommended comprehensive testing for TP53 mutations and assessment of other high-risk features, which could help guide use of non-chemotherapy–based approaches such as the BOVEN regimen.CLL: Consensus recommendations favored time-limited frontline treatment strategies for younger patients with favorable-risk disease, along with continuing observation for patients who are asymptomatic.DLBCL: Experts recommended prioritizing CAR T-cell therapy in the second-line setting for patients with primary refractory or early-relapsed disease, while noting that ctDNA/MRD monitoring still requires more evidence before routine use.